secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K/A
Filed at:   2026-07-13T20:06:29+00:00
Accession:  0001048477-26-000011
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin provides Amicus audited 2025 financials; revenue $634M, net loss $27M
------------------------------------------------------------------------------

- Amicus 2025 net product sales $634.2M, up 20% YoY from $528.3M; net loss narrowed to $27.1M from $56.1M.
- Amicus had $214.0M cash, $392.7M long-term debt, and $2.77B accumulated deficit as of Dec 31, 2025.
- BioMarin acquired Amicus for $14.50/share in cash, closing April 27, 2026; this filing provides audited financials and pro forma.
- Amicus revenue concentrated: one customer accounted for 24% of 2025 net product sales.
- Pro forma condensed combined financials as of Dec 31, 2025 included in Exhibit 99.2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000011/0001048477-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847726000011/bmrn-20260427.htm
  HTML page:      https://secwatch.observer/filing/0001048477-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer